0331 Entrada series B
BioCentury & Getty Images

Emerging Company Profile

Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

Emerging Company Profile: 5AM-incubated intracellular biologics company makes DMD its top priority

5AM-incubated intracellular biologics company Entrada is making Duchenne muscular dystrophy its top priority.

Mar 31, 2021 | 9:54 PM GMT

With $116 million to deploy from its new series B crossover round, Entrada has concluded that DMD is its top

Read the full 683 word article

How to gain access

Continue reading with a
two-week free trial.